PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/40 — A1

(11) International Publication Number: **WO 98/48795**

(43) International Publication Date: 5 November 1998 (05.11.98)

(21) International Application Number: PCT/US98/07808

(22) International Filing Date: 21 April 1998 (21.04.98)

(30) Priority Data:
60/044,431 30 April 1997 (30.04.97) US

(71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors: JIROUSEK, Michael, R.; 10342 Fawn Ridge Lane, Indianapolis, IN 46236 (US). STRAMM, Lawrence, E.; 9143 Hadway Drive, Indianapolis, IN 46256 (US). VIGNATI, Louis; 5617 North Meridian, Indianapolis, IN 46208 (US). WAYS, Douglas, K.; 4565 North Park Avenue, Indianapolis, IN 46205 (US).

(74) Agents: SKERPON, Joseph, M. et al.; Banner & Witcoff, Ltd., 11th floor, 1001 G Street, N.W., Washington, DC 20001–4597 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: THERAPEUTIC TREATMENT FOR SKIN DISORDERS

(57) Abstract

A method for reducing or inhibiting vascular permeability especially the increased vascular permeability associated with VPF/VEGF, and dermal edema exhibited with bullous pemphigoid, erythema multiforme, dermatitis herpetiformis, contact dermatitis/delayed hypersensitivity is disclosed, particularly using the β–isozyme selective PKC inhibitor, (S)–3,4–[N,N'–1,1'–((2''–ethoxy)–3'''(O)–4'''–(N,N–dimethylamino)–butane)–bis–(3,3'–indolyl)]–1(H)–pyrrole –2,5–dione and its pharmaceutically acceptable salts.